[SCIENTX] YoY Annualized Quarter Result on 30-Apr-2019 [#3]

Stock
[SCIENTX] SCIENTEX BERHAD
Announcement Date
26-Jun-2019
Admission Sponsor
-
Sponsor
-
Financial Year
31-Jul-2019
Quarter
30-Apr-2019 [#3]
Profit Trend
QoQ- 4.8%
YoY- -0.61%
Quarter Report
Latest QR
Upcoming QR
SCIENTX's Result
SCIENTX's Financial Summary
View:
Show?
Annualized Quarter Result
30/04/22 30/04/21 30/04/20 30/04/19 30/04/18 30/04/17 30/04/16 CAGR
Revenue 3,832,030 3,580,802 3,418,629 3,078,241 2,524,817 2,342,781 2,186,564 9.79%
PBT 499,652 568,602 480,098 365,353 339,681 311,580 315,232 7.97%
Tax -97,326 -118,513 -121,132 -88,965 -66,613 -62,610 -59,184 8.63%
NP 402,325 450,089 358,966 276,388 273,068 248,969 256,048 7.81%
-
NP to SH 379,853 419,438 330,749 267,060 268,692 244,994 248,973 7.29%
-
Tax Rate 19.48% 20.84% 25.23% 24.35% 19.61% 20.09% 18.77% -
Total Cost 3,429,705 3,130,713 3,059,662 2,801,853 2,251,749 2,093,812 1,930,516 10.04%
-
Net Worth 3,039,959 2,806,576 2,434,938 2,123,822 1,716,132 1,335,242 1,128,675 17.94%
Dividend
30/04/22 30/04/21 30/04/20 30/04/19 30/04/18 30/04/17 30/04/16 CAGR
Div 82,719 82,698 68,783 67,907 65,190 36,961 36,262 14.72%
Div Payout % 21.78% 19.72% 20.80% 25.43% 24.26% 15.09% 14.56% -
Equity
30/04/22 30/04/21 30/04/20 30/04/19 30/04/18 30/04/17 30/04/16 CAGR
Net Worth 3,039,959 2,806,576 2,434,938 2,123,822 1,716,132 1,335,242 1,128,675 17.94%
NOSH 1,550,999 1,550,594 515,876 515,261 488,926 462,021 226,641 37.76%
Ratio Analysis
30/04/22 30/04/21 30/04/20 30/04/19 30/04/18 30/04/17 30/04/16 CAGR
NP Margin 10.50% 12.57% 10.50% 8.98% 10.82% 10.63% 11.71% -
ROE 12.50% 14.94% 13.58% 12.57% 15.66% 18.35% 22.06% -
Per Share
30/04/22 30/04/21 30/04/20 30/04/19 30/04/18 30/04/17 30/04/16 CAGR
RPS 247.07 230.93 662.68 604.39 516.40 507.07 964.77 -20.30%
EPS 24.49 27.07 64.15 53.88 55.35 53.03 109.85 -22.12%
DPS 5.33 5.33 13.33 13.33 13.33 8.00 16.00 -16.73%
NAPS 1.96 1.81 4.72 4.17 3.51 2.89 4.98 -14.38%
Adjusted Per Share Value based on latest NOSH - 515,261
30/04/22 30/04/21 30/04/20 30/04/19 30/04/18 30/04/17 30/04/16 CAGR
RPS 247.03 230.83 220.38 198.43 162.76 151.02 140.95 9.79%
EPS 24.49 27.04 21.32 17.22 17.32 15.79 16.05 7.29%
DPS 5.33 5.33 4.43 4.38 4.20 2.38 2.34 14.69%
NAPS 1.9597 1.8092 1.5696 1.3691 1.1063 0.8607 0.7276 17.94%
Price Multiplier on Financial Quarter End Date
30/04/22 30/04/21 30/04/20 30/04/19 30/04/18 30/04/17 30/04/16 CAGR
Date 29/04/22 30/04/21 30/04/20 30/04/19 30/04/18 28/04/17 29/04/16 -
Price 3.81 4.19 8.30 8.55 7.61 8.29 12.50 -
P/RPS 1.54 1.81 1.25 1.41 1.47 1.63 1.30 2.86%
P/EPS 15.56 15.49 12.95 16.31 13.85 15.63 11.38 5.34%
EY 6.43 6.46 7.72 6.13 7.22 6.40 8.79 -5.07%
DY 1.40 1.27 1.61 1.56 1.75 0.97 1.28 1.50%
P/NAPS 1.94 2.31 1.76 2.05 2.17 2.87 2.51 -4.20%
Price Multiplier on Announcement Date
30/04/22 30/04/21 30/04/20 30/04/19 30/04/18 30/04/17 30/04/16 CAGR
Date 13/06/22 23/06/21 23/06/20 26/06/19 20/06/18 20/06/17 01/06/16 -
Price 3.50 4.26 8.77 8.56 6.71 8.37 13.04 -
P/RPS 1.42 1.84 1.32 1.42 1.30 1.65 1.35 0.84%
P/EPS 14.29 15.75 13.68 16.32 12.21 15.78 11.87 3.13%
EY 7.00 6.35 7.31 6.13 8.19 6.34 8.42 -3.03%
DY 1.52 1.25 1.52 1.56 1.99 0.96 1.23 3.58%
P/NAPS 1.79 2.35 1.86 2.05 1.91 2.90 2.62 -6.14%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment